Antibodies to OX-2/CD200 and uses thereof
AssigneeAlexion Pharmaceuticals, Inc.
InventorsKatherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
Life of this patent
Estimating the term…
Abstract
This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
Claims42
A method for treating a patient afflicted with a cancer comprising cancer cells that express CD200, the method comprising administering to the patient an anti-CD200 antibody in an amount effective to treat the cancer, wherein the anti-CD200 antibody:
- (i) inhibits the interaction between CD200 and CD200R;
- and
- (ii) comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the anti-CD200 antibody would have if it had a G2/G4 Fc constant region consisting of amino acid residues 137-462 of SEQ ID NO:13.
A method for treating a patient afflicted with a cancer comprising cancer cells that express CD200, the method comprising administering to the patient an anti-CD200 antibody in an amount effective to treat the cancer, wherein the anti-CD200 antibody:
- (i) inhibits the interaction between CD200 and CD200R;
- and
- (ii) comprises a variant Fc constant region that exhibits decreased effector function relative to the effector function of the native Fc constant region from which the variant Fc constant region was engineered.
A method for treating a patient afflicted with a cancer comprising cancer cells that express CD200, the method comprising administering to the patient an anti-CD200 antibody in an amount effective to treat the cancer, wherein the anti-CD200 antibody comprises a G2/G4 constant region and inhibits the interaction between CD200 and CD200R.
Dependencies are inferred from the claim text.